| 1 |
Straatmijer T, Biemans VBC, Moes DJAR, Hoentjen F, Ter Heine R, Maljaars PWJ, Theeuwen R, Pierik M, Duijvestein M, van der Meulen-de Jong AE; Dutch Initiative on Crohn’s and Colitis (ICC). Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease. Dig Dis Sci 2023. [PMID: 36920666 DOI: 10.1007/s10620-023-07822-7] [Reference Citation Analysis]
|
| 2 |
Oh K, Hong HS, Ham NS, Lee J, Park SH, Yang SK, Yoon H, Kim YS, Choi CH, Ye BD; Korean Association for the Study of Intestinal Diseases. Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn's disease: a KASID prospective multicenter study. Intest Res 2023;21:137-47. [PMID: 36751044 DOI: 10.5217/ir.2021.00173] [Reference Citation Analysis]
|
| 3 |
Yang Q, Wang J, Mi N, Zou Y. Literature Overview of the Relation Between Psoriasis and Alzheimer. Neuropsychiatr Dis Treat 2023;19:461-8. [PMID: 36879948 DOI: 10.2147/NDT.S403854] [Reference Citation Analysis]
|
| 4 |
Ghiboub M, Koster J, Craggs PD, Li Yim AYF, Shillings A, Hutchinson S, Bingham RP, Gatfield K, Hageman IL, Yao G, O’keefe HP, Coffin A, Patel A, Sloan LA, Mitchell DJ, Hayhow TG, Lunven L, Watson RJ, Blunt CE, Harrison LA, Bruton G, Kumar U, Hamer N, Spaull JR, Zwijnenburg DA, Welting O, Hakvoort TBM, te Velde AA, van Limbergen J, Henneman P, Prinjha RK, de Winther MPJ, Harker NR, Tough DF, de Jonge WJ. Modulation of macrophage inflammatory function through selective inhibition of the epigenetic reader protein SP140. BMC Biol 2022;20. [DOI: 10.1186/s12915-022-01380-6] [Reference Citation Analysis]
|
| 5 |
Cai Z, Wang S, Li J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front Med (Lausanne) 2021;8:765474. [PMID: 34988090 DOI: 10.3389/fmed.2021.765474] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 6 |
Jefremow A, Neurath MF. New agents for immunosuppression. Best Pract Res Clin Gastroenterol 2021;54-55:101763. [PMID: 34874846 DOI: 10.1016/j.bpg.2021.101763] [Reference Citation Analysis]
|
| 7 |
Zu M, Ma Y, Cannup B, Xie D, Jung Y, Zhang J, Yang C, Gao F, Merlin D, Xiao B. Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases. Adv Drug Deliv Rev 2021;176:113887. [PMID: 34314785 DOI: 10.1016/j.addr.2021.113887] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 8 |
Mechie NC, Burmester M, Mavropoulou E, Pilavakis Y, Kunsch S, Ellenrieder V, Amanzada A. Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn disease patients. Medicine (Baltimore) 2021;100:e25111. [PMID: 33725990 DOI: 10.1097/MD.0000000000025111] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 9 |
Iamartino L, Elajnaf T, Gall K, David J, Manhardt T, Heffeter P, Grusch M, Derdak S, Baumgartner-Parzer S, Schepelmann M, Kallay E. Effects of pharmacological calcimimetics on colorectal cancer cells over-expressing the human calcium-sensing receptor. Biochim Biophys Acta Mol Cell Res 2020;1867:118836. [PMID: 32861746 DOI: 10.1016/j.bbamcr.2020.118836] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Nakase H. Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease. Gut Liver 2020;14:7-19. [PMID: 30919602 DOI: 10.5009/gnl18203] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 11 |
Jefremow A, Neurath MF. All are Equal, Some are More Equal: Targeting IL 12 and 23 in IBD - A Clinical Perspective. Immunotargets Ther 2020;9:289-97. [PMID: 33274187 DOI: 10.2147/ITT.S282466] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 12 |
Cai W, Zhou W, Han Z, Lei J, Zhuang J, Zhu P, Wu X, Yuan W. Master regulator genes and their impact on major diseases. PeerJ 2020;8:e9952. [PMID: 33083114 DOI: 10.7717/peerj.9952] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 13 |
Solà-Tapias N, Vergnolle N, Denadai-Souza A, Barreau F. The Interplay Between Genetic Risk Factors and Proteolytic Dysregulation in the Pathophysiology of Inflammatory Bowel Disease. J Crohns Colitis 2020;14:1149-61. [PMID: 32090263 DOI: 10.1093/ecco-jcc/jjaa033] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 14 |
Ghiboub M, Koster J, Craggs PD, Li Yim AY, Shillings A, Hutchinson S, Bingham RP, Gatfield K, Hageman IL, Yao G, O’keefe HP, Coffin A, Patel A, Sloan LA, Mitchell DJ, Lunven L, Watson RJ, Blunt CE, Harrison LA, Bruton G, Kumar U, Hamer N, Spaull JR, Zwijnenburg DA, Welting O, Hakvoort TB, van Limbergen J, Henneman P, Prinjha RK, de Winther MP, Harker NR, Tough DF, de Jonge WJ. Modulation of macrophage inflammatory function through selective inhibition of the epigenetic reader protein SP140.. [DOI: 10.1101/2020.08.10.239475] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Iamartino L, Elajnaf T, Gall K, David J, Manhardt T, Heffeter P, Grusch M, Derdak S, Baumgartner-parzer S, Schepelmann M, Kallay E. Effects of pharmacological calcimimetics on colorectal cancer cells over-expressing the human calcium-sensing receptor.. [DOI: 10.1101/2020.07.09.195255] [Reference Citation Analysis]
|
| 16 |
Higashimura Y, Takagi T, Naito Y, Uchiyama K, Mizushima K, Tanaka M, Hamaguchi M, Itoh Y. Zinc Deficiency Activates the IL-23/Th17 Axis to Aggravate Experimental Colitis in Mice. J Crohns Colitis 2020;14:856-66. [PMID: 31783404 DOI: 10.1093/ecco-jcc/jjz193] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 17 |
Painchart C, Brabant S, Duveau N, Nachury M, Desreumaux P, Branche J, Gérard R, Prevost CLD, Wils P, Lambin T, Boualit M, Labalette M, Pariente B. Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease. Dig Dis Sci 2020;65:1445-52. [PMID: 31599389 DOI: 10.1007/s10620-019-05865-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 18 |
Nakase H. Treatment of inflammatory bowel disease from the immunological perspective. Immunological Medicine 2020;43:79-86. [DOI: 10.1080/25785826.2020.1751934] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 19 |
DeKuiper JL, Cooperider HE, Lubben N, Ancel CM, Coussens PM. Mycobacterium avium Subspecies paratuberculosis Drives an Innate Th17-Like T Cell Response Regardless of the Presence of Antigen-Presenting Cells. Front Vet Sci 2020;7:108. [PMID: 32258066 DOI: 10.3389/fvets.2020.00108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 20 |
Mariane Steigleder K, Lopes Ponte Neto F, Kibune Nagasako C, Franco Leal R. Anti-Integrins, Anti-Interleukin 12/23p40, and JAK Inhibitors for the Inflammatory Bowel Disease Treatment. Biological Therapy for Inflammatory Bowel Disease 2020. [DOI: 10.5772/intechopen.90536] [Reference Citation Analysis]
|
| 21 |
Manthey CL, Moore BA, Chen Y, Loza MJ, Yao X, Liu H, Belkowski SM, Raymond-Parks H, Dunford PJ, Leon F, Towne JE, Plevy SE. The CSF-1-receptor inhibitor, JNJ-40346527 (PRV-6527), reduced inflammatory macrophage recruitment to the intestinal mucosa and suppressed murine T cell mediated colitis. PLoS One 2019;14:e0223918. [PMID: 31710624 DOI: 10.1371/journal.pone.0223918] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 22 |
DeKuiper JL, Coussens PM. Inflammatory Th17 responses to infection with Mycobacterium avium subspecies paratuberculosis (MAP) in cattle and their potential role in development of Johne's disease. Vet Immunol Immunopathol 2019;218:109954. [PMID: 31733610 DOI: 10.1016/j.vetimm.2019.109954] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 23 |
DeKuiper JL, Coussens PM. Mycobacterium avium sp. paratuberculosis (MAP) induces IL-17a production in bovine peripheral blood mononuclear cells (PBMCs) and enhances IL-23R expression in-vivo and in-vitro. Vet Immunol Immunopathol 2019;218:109952. [PMID: 31593889 DOI: 10.1016/j.vetimm.2019.109952] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 24 |
Na YR, Stakenborg M, Seok SH, Matteoli G. Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD. Nat Rev Gastroenterol Hepatol 2019;16:531-43. [PMID: 31312042 DOI: 10.1038/s41575-019-0172-4] [Cited by in Crossref: 272] [Cited by in F6Publishing: 261] [Article Influence: 68.0] [Reference Citation Analysis]
|
| 25 |
Schön MP. Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders. Front Immunol 2019;10:1764. [PMID: 31402919 DOI: 10.3389/fimmu.2019.01764] [Cited by in Crossref: 68] [Cited by in F6Publishing: 73] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 26 |
Meinderts SM, Gerritsma JJ, Sins JWR, de Boer M, van Leeuwen K, Biemond BJ, Rijneveld AW, Kerkhoffs JH, Habibi A, van Bruggen R, Kuijpers TW, van der Schoot E, Pirenne F, Fijnvandraat K, Tanck MW, van den Berg TK. Identification of genetic biomarkers for alloimmunization in sickle cell disease. Br J Haematol 2019;186:887-99. [PMID: 31168801 DOI: 10.1111/bjh.15998] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 27 |
Khanna R, Levesque BG, Mcdonald JW, Feagan BG. Therapy for Crohn's Disease. Evidence-based Gastroenterology and Hepatology 4e 2019. [DOI: 10.1002/9781119211419.ch10] [Reference Citation Analysis]
|
| 28 |
Ma H, Tao W, Zhu S. T lymphocytes in the intestinal mucosa: defense and tolerance. Cell Mol Immunol 2019;16:216-24. [PMID: 30787416 DOI: 10.1038/s41423-019-0208-2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 29 |
Neurath MF. IL-23 in inflammatory bowel diseases and colon cancer. Cytokine Growth Factor Rev 2019;45:1-8. [PMID: 30563755 DOI: 10.1016/j.cytogfr.2018.12.002] [Cited by in Crossref: 84] [Cited by in F6Publishing: 87] [Article Influence: 16.8] [Reference Citation Analysis]
|
| 30 |
Saniabadi AR, Tanaka T, Yamamoto T, Kruis W, Sacco R. Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. J Clin Apher. 2019;34:51-60. [PMID: 30407662 DOI: 10.1002/jca.21670] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 31 |
Visvanathan S, Baum P, Salas A, Vinisko R, Schmid R, Grebe KM, Davis JW, Wallace K, Böcher WO, Padula SJ, Fine JS, Panés J. Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study. J Crohns Colitis 2018;12:1170-9. [PMID: 30032288 DOI: 10.1093/ecco-jcc/jjy099] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 32 |
Feagan BG, Panés J, Ferrante M, Kaser A, D'haens GR, Sandborn WJ, Louis E, Neurath MF, Franchimont D, Dewit O, Seidler U, Kim K, Selinger C, Padula SJ, Herichova I, Robinson AM, Wallace K, Zhao J, Minocha M, Othman AA, Soaita A, Visvanathan S, Hall DB, Böcher WO. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. The Lancet Gastroenterology & Hepatology 2018;3:671-80. [DOI: 10.1016/s2468-1253(18)30233-4] [Cited by in Crossref: 100] [Cited by in F6Publishing: 88] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 33 |
Rowan CR, Keegan D, Byrne K, Cullen G, Mulcahy HE, Sheridan J, Ryan EJ, de Vries A, D'Haens G, Doherty GA. Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study. Aliment Pharmacol Ther 2018;48:333-9. [PMID: 29920697 DOI: 10.1111/apt.14834] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 34 |
Schön MP, Erpenbeck L. The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis. Front Immunol 2018;9:1323. [PMID: 29963046 DOI: 10.3389/fimmu.2018.01323] [Cited by in Crossref: 114] [Cited by in F6Publishing: 119] [Article Influence: 22.8] [Reference Citation Analysis]
|
| 35 |
Nash P. Psoriatic arthritis: novel targets add to a therapeutic renaissance. Lancet 2018;391:2187-9. [PMID: 29893210 DOI: 10.1016/S0140-6736(18)31217-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 36 |
Sasso GL, Schlage WK, Phillips B, Peitsch MC, Hoeng J. Animal Inhalation Models to Investigate Modulation of Inflammatory Bowel Diseases. Experimental Animal Models of Human Diseases - An Effective Therapeutic Strategy 2018. [DOI: 10.5772/intechopen.69569] [Reference Citation Analysis]
|
| 37 |
Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, Gao LL, Davis HM, Hanauer SB, Feagan BG, Ghosh S, Sandborn WJ. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology 2018;154:1660-71. [PMID: 29409871 DOI: 10.1053/j.gastro.2018.01.043] [Cited by in Crossref: 134] [Cited by in F6Publishing: 134] [Article Influence: 26.8] [Reference Citation Analysis]
|
| 38 |
Argollo M, Fiorino G, Hindryckx P, Peyrin-biroulet L, Danese S. Novel therapeutic targets for inflammatory bowel disease. Journal of Autoimmunity 2017;85:103-16. [DOI: 10.1016/j.jaut.2017.07.004] [Cited by in Crossref: 68] [Cited by in F6Publishing: 73] [Article Influence: 11.3] [Reference Citation Analysis]
|
| 39 |
Danese S, Bonovas S, Peyrin-Biroulet L. Positioning Ustekinumab in Crohn's Disease: From Clinical Evidence to Clinical Practice. J Crohns Colitis 2017;11:1258-66. [PMID: 28575273 DOI: 10.1093/ecco-jcc/jjx079] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 40 |
Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, Martel M, Seidman E, Afif W. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2017;15:1427-1434.e2. [PMID: 28365485 DOI: 10.1016/j.cgh.2017.03.032] [Cited by in Crossref: 150] [Cited by in F6Publishing: 153] [Article Influence: 25.0] [Reference Citation Analysis]
|
| 41 |
Li J, Doty AL, Tang Y, Berrie D, Iqbal A, Tan SA, Clare-Salzler MJ, Wallet SM, Glover SC. Enrichment of IL-17A+ IFN-γ+ and IL-22+ IFN-γ+ T cell subsets is associated with reduction of NKp44+ ILC3s in the terminal ileum of Crohn's disease patients. Clin Exp Immunol 2017;190:143-53. [PMID: 28586085 DOI: 10.1111/cei.12996] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 42 |
Denmark V. Safety and Immunogenicity of Biologic Therapy in Inflammatory Bowel Disease. Hospital Medicine Clinics 2017;6:425-435. [DOI: 10.1016/j.ehmc.2017.04.009] [Reference Citation Analysis]
|
| 43 |
Panés J, Alfaro I. New treatment strategies for ulcerative colitis. Expert Rev Clin Immunol 2017;13:963-73. [PMID: 28617055 DOI: 10.1080/1744666X.2017.1343668] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 44 |
Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol 2017;14:269-78. [PMID: 28144028 DOI: 10.1038/nrgastro.2016.208] [Cited by in Crossref: 315] [Cited by in F6Publishing: 287] [Article Influence: 52.5] [Reference Citation Analysis]
|
| 45 |
Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, Louis E, Franchimont D, Dewit O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, Böcher WO. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 2017;389:1699-709. [PMID: 28411872 DOI: 10.1016/S0140-6736(17)30570-6] [Cited by in Crossref: 301] [Cited by in F6Publishing: 292] [Article Influence: 50.2] [Reference Citation Analysis]
|
| 46 |
Saeed MA, Ng GZ, Däbritz J, Wagner J, Judd L, Han JX, Dhar P, Kirkwood CD, Sutton P. Protease-activated Receptor 1 Plays a Proinflammatory Role in Colitis by Promoting Th17-related Immunity. Inflamm Bowel Dis 2017;23:593-602. [PMID: 28296821 DOI: 10.1097/MIB.0000000000001045] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 47 |
Schäkel K, Schön MP, Ghoreschi K. [Pathogenesis of psoriasis]. Hautarzt 2016;67:422-31. [PMID: 27246016 DOI: 10.1007/s00105-016-3800-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 48 |
Li J, Wei H, Krystek SR Jr, Bond D, Brender TM, Cohen D, Feiner J, Hamacher N, Harshman J, Huang RY, Julien SH, Lin Z, Moore K, Mueller L, Noriega C, Sejwal P, Sheppard P, Stevens B, Chen G, Tymiak AA, Gross ML, Schneeweis LA. Mapping the Energetic Epitope of an Antibody/Interleukin-23 Interaction with Hydrogen/Deuterium Exchange, Fast Photochemical Oxidation of Proteins Mass Spectrometry, and Alanine Shave Mutagenesis. Anal Chem 2017;89:2250-8. [PMID: 28193005 DOI: 10.1021/acs.analchem.6b03058] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 49 |
Velikova T, Kyurkchiev D, Spassova Z, Karakolev I, Ivanova-Todorova E, Altankova I, Stanilova S. Alterations in cytokine gene expression profile in colon mucosa of Inflammatory Bowel Disease patients on different therapeutic regimens. Cytokine. 2017;92:12-19. [PMID: 28088612 DOI: 10.1016/j.cyto.2017.01.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 50 |
Rashid F, Lichtenstein GR. New Non-anti-TNF-α Biological Therapies for the Treatment of Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease 2017. [DOI: 10.1007/978-3-319-49215-5_35] [Reference Citation Analysis]
|
| 51 |
Wollheim FA. Enteropathic Arthritis. Kelley and Firestein's Textbook of Rheumatology 2017. [DOI: 10.1016/b978-0-323-31696-5.00078-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 52 |
Gultekin FA, Emre AU, Celik SK, Barut F, Tali U, Sumer D, Turkcu UO. Effects of humanin on experimental colitis induced by 2,4,6-trinitrobenzene sulphonic acid in rats. Saudi J Gastroenterol 2017;23:105-11. [PMID: 28361841 DOI: 10.4103/sjg.SJG_318_16] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 53 |
Aydemir Y, Pınar A, Hızal G, Demir H, Saltık Temizel İN, Özen H, Akbıyık F, Yüce A. Neutrophil volume distribution width as a new marker in detecting inflammatory bowel disease activation. Int Jnl Lab Hem 2017;39:51-7. [DOI: 10.1111/ijlh.12574] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 54 |
Hirata Y, Ihara S, Koike K. Targeting the complex interactions between microbiota, host epithelial and immune cells in inflammatory bowel disease. Pharmacol Res 2016;113:574-84. [PMID: 27702681 DOI: 10.1016/j.phrs.2016.09.044] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 55 |
Zhou Z, Ding M, Huang L, Gilkeson G, Lang R, Jiang W. Toll-like receptor-mediated immune responses in intestinal macrophages; implications for mucosal immunity and autoimmune diseases. Clin Immunol 2016;173:81-6. [PMID: 27620642 DOI: 10.1016/j.clim.2016.09.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 56 |
Li J, Leyva-castillo JM, Hener P, Eisenmann A, Zaafouri S, Jonca N, Serre G, Birling M, Li M. Counterregulation between thymic stromal lymphopoietin– and IL-23–driven immune axes shapes skin inflammation in mice with epidermal barrier defects. Journal of Allergy and Clinical Immunology 2016;138:150-161.e13. [DOI: 10.1016/j.jaci.2016.01.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 57 |
Khorrami S, Ginard D, Marín-Jiménez I, Chaparro M, Sierra M, Aguas M, Sicilia B, García-Sánchez V, Suarez C, Villoria A, Taxonera C, Velasco-Guardado A, Martínez-González J, Gisbert JP. Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort. Inflamm Bowel Dis 2016;22:1662-9. [PMID: 27306072 DOI: 10.1097/MIB.0000000000000842] [Cited by in Crossref: 122] [Cited by in F6Publishing: 92] [Article Influence: 17.4] [Reference Citation Analysis]
|
| 58 |
Adar T, Shteingart S, Ben-Ya'acov A, Shitrit AB, Livovsky DM, Shmorak S, Mahamid M, Melamud B, Vernea F, Goldin E. The Importance of Intestinal Eotaxin-1 in Inflammatory Bowel Disease: New Insights and Possible Therapeutic Implications. Dig Dis Sci 2016;61:1915-24. [PMID: 26874691 DOI: 10.1007/s10620-016-4047-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 59 |
Mentzer A, Nayee S, Omar Y, Hullah E, Taylor K, Goel R, Bye H, Shembesh T, Elliott TR, Campbell H, Patel P, Nolan A, Mansfield J, Challacombe S, Escudier M, Mathew CG, Sanderson JD, Prescott NJ. Genetic Association Analysis Reveals Differences in the Contribution of NOD2 Variants to the Clinical Phenotypes of Orofacial Granulomatosis. Inflamm Bowel Dis 2016;22:1552-8. [PMID: 27306066 DOI: 10.1097/MIB.0000000000000844] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 60 |
Truong AD, Park B, Ban J, Hong YH. The novel chicken interleukin 26 protein is overexpressed in T cells and induces proinflammatory cytokines. Vet Res 2016;47:65. [PMID: 27312894 DOI: 10.1186/s13567-016-0342-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 61 |
Roth S, Spalinger MR, Gottier C, Biedermann L, Zeitz J, Lang S, Weber A, Rogler G, Scharl M. Bilberry-Derived Anthocyanins Modulate Cytokine Expression in the Intestine of Patients with Ulcerative Colitis. PLoS One. 2016;11:e0154817. [PMID: 27152519 DOI: 10.1371/journal.pone.0154817] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 62 |
Durchschein F, Petritsch W, Hammer HF. Diet therapy for inflammatory bowel diseases: The established and the new. World J Gastroenterol 2016; 22(7): 2179-2194 [PMID: 26900283 DOI: 10.3748/wjg.v22.i7.2179] [Cited by in CrossRef: 103] [Cited by in F6Publishing: 101] [Article Influence: 14.7] [Reference Citation Analysis]
|
| 63 |
Harris KA, Horst S, Gadani A, Nohl A, Annis K, Duley C, Beaulieu D, Ghazi L, Schwartz DA. Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab. Inflamm Bowel Dis 2016;22:397-401. [PMID: 26752468 DOI: 10.1097/MIB.0000000000000624] [Cited by in Crossref: 69] [Cited by in F6Publishing: 56] [Article Influence: 9.9] [Reference Citation Analysis]
|
| 64 |
Sinh P, Fiocchi C, Achkar J. Immune Based Therapies for Inflammatory Bowel Disease. Immune Rebalancing 2016. [DOI: 10.1016/b978-0-12-803302-9.00003-8] [Reference Citation Analysis]
|
| 65 |
Jiminez JA, Uwiera TC, Douglas Inglis G, Uwiera RR. Animal models to study acute and chronic intestinal inflammation in mammals. Gut Pathog 2015;7:29. [PMID: 26561503 DOI: 10.1186/s13099-015-0076-y] [Cited by in Crossref: 119] [Cited by in F6Publishing: 122] [Article Influence: 14.9] [Reference Citation Analysis]
|
| 66 |
Boehncke W. Etiology and Pathogenesis of Psoriasis. Rheumatic Disease Clinics of North America 2015;41:665-75. [DOI: 10.1016/j.rdc.2015.07.013] [Cited by in Crossref: 95] [Cited by in F6Publishing: 107] [Article Influence: 11.9] [Reference Citation Analysis]
|
| 67 |
Boehncke WH, Schön MP. Psoriasis. Lancet 2015;386:983-94. [PMID: 26025581 DOI: 10.1016/S0140-6736(14)61909-7] [Cited by in Crossref: 1383] [Cited by in F6Publishing: 1098] [Article Influence: 172.9] [Reference Citation Analysis]
|
| 68 |
Quiniou C, Domínguez-punaro M, Cloutier F, Erfani A, Ennaciri J, Sivanesan D, Sanchez M, Chognard G, Hou X, Rivera JC, Beauchamp C, Charron G, Vilquin M, Kuchroo V, Michnick S, Rioux JD, Lesage S, Chemtob S. Specific targeting of the IL-23 receptor, using a novel small peptide noncompetitive antagonist, decreases the inflammatory response. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2014;307:R1216-30. [DOI: 10.1152/ajpregu.00540.2013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 69 |
Peng JC, Shen J, Ran ZH. Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease. J Dig Dis 2014;15:585-90. [PMID: 25251263 DOI: 10.1111/1751-2980.12193] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 70 |
Kopylov U, Afif W, Cohen A, Bitton A, Wild G, Bessissow T, Wyse J, Al-Taweel T, Szilagyi A, Seidman E. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease--the McGill experience. J Crohns Colitis 2014;8:1516-22. [PMID: 24996483 DOI: 10.1016/j.crohns.2014.06.005] [Cited by in Crossref: 112] [Cited by in F6Publishing: 113] [Article Influence: 12.4] [Reference Citation Analysis]
|
| 71 |
Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715 [PMID: 25110409 DOI: 10.3748/wjg.v20.i29.9699] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 72 |
Guan Q, Burtnick HA, Qing G, Weiss CR, Ma AG, Ma Y, Warrington RJ, Peng Z. Employing an IL-23 p19 vaccine to block IL-23 ameliorates chronic murine colitis. Immunotherapy 2013;5:1313-22. [PMID: 24283842 DOI: 10.2217/imt.13.141] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 73 |
Nishise S, Abe Y, Nomura E, Sato T, Sasaki Y, Iwano D, Yoshizawa K, Yagi M, Nishise Y, Ueno Y. Relationship Between Tumor Necrosis Factor-α Release and Granulocyte and Monocyte Adsorption to Cellulose Acetate Beads: TNF-α Release by Leukocyte Adsorption. Ther Apher Dial 2014;18:252-7. [DOI: 10.1111/1744-9987.12212] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 74 |
Tuskey A, Behm BW. Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn’s disease. Clin Exp Gastroenterol. 2014;7:173-179. [PMID: 24904220 DOI: 10.2147/ceg.s39518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 75 |
Hayakawa N, Noguchi M, Takeshita S, Eviryanti A, Seki Y, Nishio H, Yokoyama R, Noguchi M, Shuto M, Shima Y, Kuribayashi K, Kageyama S, Eda H, Suzuki M, Hatta T, Iemura S, Natsume T, Tanabe I, Nakagawa R, Shiozaki M, Sakurai K, Shoji M, Andou A, Yamamoto T. Structure-activity relationship study, target identification, and pharmacological characterization of a small molecular IL-12/23 inhibitor, APY0201. Bioorg Med Chem 2014;22:3021-9. [PMID: 24767819 DOI: 10.1016/j.bmc.2014.03.036] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 76 |
Khanna R, Feagan BG. Ustekinumab for the treatment of Crohn’s disease. Immunotherapy. 2013;5:803-815. [PMID: 23902548 DOI: 10.2217/imt.13.81] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 77 |
Correction of Microbiota Disturbances or Antagonism Against Specific Pathogens in IBD. Intestinal Microbiota in Health and Disease 2014. [DOI: 10.1201/b16442-12] [Reference Citation Analysis]
|
| 78 |
Li J, Chen C, Cao XN, Wang GH, Hu JB, Wang J. Efficacy of topical versus oral 5-aminosalicylate for treatment of 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats. J Huazhong Univ Sci Technolog Med Sci 2014;34:59-65. [PMID: 24496680 DOI: 10.1007/s11596-014-1232-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 79 |
Mozaffari S, Nikfar S, Abdolghaffari AH, Abdollahi M. New biologic therapeutics for ulcerative colitis and Crohn’s disease. Expert Opin Biol Ther. 2014;14:583-600. [PMID: 24502344 DOI: 10.1517/14712598.2014.885945] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 80 |
McLean MH, Neurath MF, Durum SK. Targeting interleukins for the treatment of inflammatory bowel disease-what lies beyond anti-TNF therapy? Inflamm Bowel Dis 2014;20:389-97. [PMID: 24356385 DOI: 10.1097/01.MIB.0000437616.37000.41] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 81 |
Denmark VK, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update. Expert Review of Clinical Immunology 2014;9:77-92. [DOI: 10.1586/eci.12.91] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 82 |
Adorini L, Amuchastegui S, Corsiero E, Laverny G, Le Meur T, Penna G. Vitamin D receptor agonists as anti-inflammatory agents. Expert Review of Clinical Immunology 2014;3:477-89. [DOI: 10.1586/1744666x.3.4.477] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 83 |
Ogino T, Nishimura J, Barman S, Kayama H, Uematsu S, Okuzaki D, Osawa H, Haraguchi N, Uemura M, Hata T, Takemasa I, Mizushima T, Yamamoto H, Takeda K, Doki Y, Mori M. Increased Th17-inducing activity of CD14+ CD163 low myeloid cells in intestinal lamina propria of patients with Crohn's disease. Gastroenterology 2013;145:1380-91.e1. [PMID: 23993972 DOI: 10.1053/j.gastro.2013.08.049] [Cited by in Crossref: 88] [Cited by in F6Publishing: 88] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 84 |
Meena NK, Verma R, Verma N, Ahuja V, Paul J. TLR4 D299G polymorphism modulates cytokine expression in ulcerative colitis. J Clin Gastroenterol 2013;47:773-80. [PMID: 23470644 DOI: 10.1097/MCG.0b013e31828a6e93] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 85 |
Badiei A, Moosakhani F, Hamidi A, Sami M. The effect of Protexin on prevention of ileocecal infection by Mycobacterium avium subspecies paratuberculosis in dairy calves. Journal of Dairy Science 2013;96:6535-8. [DOI: 10.3168/jds.2012-5535] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 86 |
Brunsing RL, Owens KS, Prossnitz ER. The G protein-coupled estrogen receptor (GPER) agonist G-1 expands the regulatory T-cell population under TH17-polarizing conditions. J Immunother 2013;36:190-6. [PMID: 23502766 DOI: 10.1097/CJI.0b013e31828d8e3b] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 87 |
Barrett CW, Singh K, Motley AK, Lintel MK, Matafonova E, Bradley AM, Ning W, Poindexter SV, Parang B, Reddy VK. Dietary selenium deficiency exacerbates DSS-induced epithelial injury and AOM/DSS-induced tumorigenesis. PLoS One. 2013;8:e67845. [PMID: 23861820 DOI: 10.1371/journal.pone.0067845] [Cited by in Crossref: 66] [Cited by in F6Publishing: 71] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 88 |
Zulfiqar F, Hozo I, Rangarajan S, Mariuzza RA, Dziarski R, Gupta D. Genetic Association of Peptidoglycan Recognition Protein Variants with Inflammatory Bowel Disease. PLoS One 2013;8:e67393. [PMID: 23840689 DOI: 10.1371/journal.pone.0067393] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 89 |
Löwenberg M, D’Haens G. Novel targets for inflammatory bowel disease therapeutics. Curr Gastroenterol Rep. 2013;15:311. [PMID: 23314806 DOI: 10.1007/s11894-012-0311-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 90 |
Wu NL, Huang DY, Hsieh SL, Hsiao CH, Lee TA, Lin WW. EGFR-driven up-regulation of decoy receptor 3 in keratinocytes contributes to the pathogenesis of psoriasis. Biochim Biophys Acta. 2013;1832:1538-1548. [PMID: 23707413 DOI: 10.1016/j.bbadis.2013.05.020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 91 |
Choi EY, Cho KK, Choi IS. Inflammatory Bowel Disease and Cytokine. Journal of Life Science 2013;23:448-461. [DOI: 10.5352/jls.2013.23.3.448] [Reference Citation Analysis]
|
| 92 |
Blander JM, Torchinsky MB, Campisi L. Revisiting the old link between infection and autoimmune disease with commensals and T helper 17 cells. Immunol Res 2012;54:50-68. [PMID: 22460741 DOI: 10.1007/s12026-012-8311-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 93 |
Tominaga K, Nakano M, Hoshino M, Kanke K, Hiraishi H. Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone. BMC Gastroenterol. 2013;13:41. [PMID: 23452668 DOI: 10.1186/1471-230x-13-41] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 94 |
Wollheim FA, Ronneberger M. Enteropathic Arthritis. Kelley's Textbook of Rheumatology 2013. [DOI: 10.1016/b978-1-4377-1738-9.00078-5] [Reference Citation Analysis]
|
| 95 |
Blonski W, Aberra F, Lichtenstein GR. Biologic Therapies. Pediatric Inflammatory Bowel Disease 2013. [DOI: 10.1007/978-1-4614-5061-0_34] [Reference Citation Analysis]
|
| 96 |
Wolowczuk I, Pariente B, Allez M, Chamaillard M. IL17 and/or IL22 as Potential Target(s) for Crohn’s Disease. IL-17, IL-22 and Their Producing Cells: Role in Inflammation and Autoimmunity 2013. [DOI: 10.1007/978-3-0348-0522-3_20] [Reference Citation Analysis]
|
| 97 |
Macoch M, Morzadec C, Fardel O, Vernhet L. Inorganic arsenic impairs differentiation and functions of human dendritic cells. Toxicol Appl Pharmacol 2013;266:204-13. [PMID: 23164666 DOI: 10.1016/j.taap.2012.11.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 98 |
Zhang S, Li R, Qing Q, Zhang T, Zhou Y, Chen Y, Zhang Y, Lin S, Liu Y; Cochrane IBD Group. Anti-IL-17 monoclonal antibody for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd010147] [Reference Citation Analysis]
|
| 99 |
Kim SW, Kim ES, Moon CM, Kim TI, Kim WH, Cheon JH. Abnormal genetic and epigenetic changes in signal transducer and activator of transcription 4 in the pathogenesis of inflammatory bowel diseases. Dig Dis Sci 2012;57:2600-7. [PMID: 22569826 DOI: 10.1007/s10620-012-2199-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 100 |
Queiro R, Ginard D. Ustekinumab en la artritis psoriásica y la enfermedad de Crohn. Actas Dermo-Sifiliográficas 2012;103:65-72. [DOI: 10.1016/s0001-7310(12)70011-x] [Reference Citation Analysis]
|
| 101 |
Ando Y, Yang GX, Tsuda M, Kawata K, Zhang W, Nakajima T, Tsuneyama K, Leung P, Lian ZX, Okazaki K, Ridgway WM, Norman GL, Ansari AA, He XS, Coppel RL, Gershwin ME. The immunobiology of colitis and cholangitis in interleukin-23p19 and interleukin-17A deleted dominant negative form of transforming growth factor beta receptor type II mice. Hepatology 2012;56:1418-26. [PMID: 22532156 DOI: 10.1002/hep.25803] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 102 |
Ogawa K, Matsumoto T, Esaki M, Torisu T, Iida M. Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab. J Crohns Colitis 2012;6:529-35. [PMID: 22398057 DOI: 10.1016/j.crohns.2011.10.010] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 103 |
Liu S, Liu Y, Yin Y, Zhang X, Ma X. A case-control study of interleukin-12 1188A/C polymorphism in obsessive-compulsive disorder in Chinese population. Acta Neuropsychiatr 2012;24:172-5. [PMID: 26953011 DOI: 10.1111/j.1601-5215.2011.00616.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 104 |
Glas J, Seiderer J, Wagner J, Olszak T, Fries C, Tillack C, Friedrich M, Beigel F, Stallhofer J, Steib C. Analysis of IL12B gene variants in inflammatory bowel disease. PLoS One. 2012;7:e34349. [PMID: 22479607 DOI: 10.1371/journal.pone.0034349] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 105 |
Perrier C, Rutgeerts P. Cytokine blockade in inflammatory bowel diseases. Immunotherapy. 2011;3:1341-1352. [PMID: 22053885 DOI: 10.2217/imt.11.122] [Cited by in Crossref: 56] [Cited by in F6Publishing: 65] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 106 |
Lindebo Holm T, Poulsen SS, Markholst H, Reedtz-Runge S. Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease. Int J Inflam 2012;2012:412178. [PMID: 22536543 DOI: 10.1155/2012/412178] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 107 |
Naser SA, Arce M, Khaja A, Fernandez M, Naser N, Elwasila S, Thanigachalam S. Role of ATG16L, NOD2 and IL23R in Crohn’s disease pathogenesis. World J Gastroenterol 2012; 18(5): 412-424 [PMID: 22346247 DOI: 10.3748/wjg.v18.i5.412] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 72] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 108 |
Olsen T, Rismo R, Cui G, Goll R, Christiansen I, Florholmen J. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Cytokine. 2011;56:633-640. [PMID: 21945121 DOI: 10.1016/j.cyto.2011.08.036] [Cited by in Crossref: 101] [Cited by in F6Publishing: 106] [Article Influence: 8.4] [Reference Citation Analysis]
|
| 109 |
Gad M, Ravn P, Søborg DA, Lund-Jensen K, Ouwehand AC, Jensen SS. Regulation of the IL-10/IL-12 axis in human dendritic cells with probiotic bacteria. FEMS Immunol Med Microbiol. 2011;63:93-107. [PMID: 21707779 DOI: 10.1111/j.1574-695x.2011.00835.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 110 |
Wang Q, Franks HA, Porte J, El Refaee M, Shah S, Crooks J, Patel PM, Jackson AM. Novel approach for interleukin-23 up-regulation in human dendritic cells and the impact on T helper type 17 generation. Immunology 2011;134:60-72. [PMID: 21718315 DOI: 10.1111/j.1365-2567.2011.03467.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 111 |
Sansó Sureda A, Rocamora Durán V, Sapiña Camaró A, Royo Escosa V, Bosque López MJ. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis]. Gastroenterol Hepatol 2011;34:546-50. [PMID: 21665330 DOI: 10.1016/j.gastrohep.2011.04.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 112 |
Xu J, Yang Y, Qiu G, Lal G, Yin N, Wu Z, Bromberg JS, Ding Y. Stat4 is critical for the balance between Th17 cells and regulatory T cells in colitis. J Immunol. 2011;186:6597-6606. [PMID: 21525389 DOI: 10.4049/jimmunol.1004074] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 113 |
Mahurkar S, Banerjee R, Rani VS, Thakur N, Rao GV, Reddy DN, Chandak GR. Common variants in NOD2 and IL23R are not associated with inflammatory bowel disease in Indians. J Gastroenterol Hepatol 2011;26:694-9. [PMID: 21155887 DOI: 10.1111/j.1440-1746.2010.06533.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 114 |
Guan Q, Ma Y, Hillman CL, Qing G, Ma AG, Weiss CR, Zhou G, Bai A, Warrington RJ, Bernstein CN. Targeting IL-12/IL-23 by employing a p40 peptide-based vaccine ameliorates TNBS-induced acute and chronic murine colitis. Mol Med. 2011;17:646-656. [PMID: 21424108 DOI: 10.2119/molmed.2010.00252] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 115 |
Chen X, Wang L, Hu B, Guo M, Barnard J, Zhu X. Pathway-based analysis for genome-wide association studies using supervised principal components. Genet Epidemiol 2010;34:716-24. [PMID: 20842628 DOI: 10.1002/gepi.20532] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 116 |
Maher SG, Reynolds JV. Basic Concepts of Inflammation and its Role in Carcinogenesis. Inflammation and Gastrointestinal Cancers 2011. [DOI: 10.1007/978-3-642-03503-6_1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 117 |
Wang K, Li M, Hakonarson H. Analysing biological pathways in genome-wide association studies. Nat Rev Genet 2010;11:843-54. [PMID: 21085203 DOI: 10.1038/nrg2884] [Cited by in Crossref: 607] [Cited by in F6Publishing: 638] [Article Influence: 46.7] [Reference Citation Analysis]
|
| 118 |
Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol. 2011;163:50-58. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 72] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 119 |
Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol 2011;163:50-8. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 120 |
Hayee B, Rahman FZ, Sewell G, Smith AM, Segal AW. Crohn's disease as an immunodeficiency. Expert Rev Clin Immunol 2010;6:585-96. [PMID: 20594132 DOI: 10.1586/eci.10.32] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 121 |
Jürgens M, Laubender RP, Hartl F, Weidinger M, Seiderer J, Wagner J, Wetzke M, Beigel F, Pfennig S, Stallhofer J, Schnitzler F, Tillack C, Lohse P, Göke B, Glas J, Ochsenkühn T, Brand S. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol 2010;105:1811-9. [PMID: 20197757 DOI: 10.1038/ajg.2010.95] [Cited by in Crossref: 116] [Cited by in F6Publishing: 114] [Article Influence: 8.9] [Reference Citation Analysis]
|
| 122 |
Jensen SS, Gad M. Differential induction of inflammatory cytokines by dendritic cells treated with novel TLR-agonist and cytokine based cocktails: targeting dendritic cells in autoimmunity. J Inflamm (Lond) 2010;7:37. [PMID: 20663192 DOI: 10.1186/1476-9255-7-37] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 123 |
Lindberg A, Eberhardson M, Karlsson M, Karlén P. Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol. 2010;10:73. [PMID: 20604939 DOI: 10.1186/1471-230x-10-73] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 124 |
Sands BE, Jacobson EW, Sylwestrowicz T, Younes Z, Dryden G, Fedorak R, Greenbloom S. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflamm Bowel Dis 2010;16:1209-18. [PMID: 19918967 DOI: 10.1002/ibd.21159] [Cited by in Crossref: 59] [Cited by in F6Publishing: 65] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 125 |
Glas J, Seiderer J, Nagy M, Fries C, Beigel F, Weidinger M, Pfennig S, Klein W, Epplen JT, Lohse P. Evidence for STAT4 as a common autoimmune gene: rs7574865 is associated with colonic Crohn's disease and early disease onset. PLoS One. 2010;5:e10373. [PMID: 20454450 DOI: 10.1371/journal.pone.0010373] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 126 |
Kamada N, Hisamatsu T, Honda H, Kobayashi T, Chinen H, Takayama T, Kitazume MT, Okamoto S, Koganei K, Sugita A, Kanai T, Hibi T. TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease. Inflamm Bowel Dis 2010;16:568-75. [PMID: 19834969 DOI: 10.1002/ibd.21124] [Cited by in Crossref: 94] [Cited by in F6Publishing: 92] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 127 |
Ryan C, Thrash B, Warren RB, Menter A. The use of ustekinumab in autoimmune disease. Expert Opinion on Biological Therapy 2010;10:587-604. [DOI: 10.1517/14712591003724670] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 128 |
Elliott M, Benson J, Blank M, Brodmerkel C, Baker D, Sharples KR, Szapary P. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann N Y Acad Sci. 2009;1182:97-110. [PMID: 20074279 DOI: 10.1111/j.1749-6632.2009.05070.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 129 |
Sands BE, Siegel CA. Crohn's Disease. Sleisenger and Fordtran's Gastrointestinal and Liver Disease 2010. [DOI: 10.1016/b978-1-4160-6189-2.00111-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 130 |
Kozlowski S, Cherney B, Donnelly RP. Hurdles and Leaps for Protein Therapeutics: Cytokines and Inflammation. Annals of the New York Academy of Sciences 2009;1182:146-60. [DOI: 10.1111/j.1749-6632.2009.05158.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 131 |
Plomin R, Haworth CMA, Davis OSP. Common disorders are quantitative traits. Nat Rev Genet 2009;10:872-8. [DOI: 10.1038/nrg2670] [Cited by in Crossref: 464] [Cited by in F6Publishing: 500] [Article Influence: 33.1] [Reference Citation Analysis]
|
| 132 |
Chen B, Zeng Z, Hou J, Chen M, Gao X, Hu P. Association of interleukin-17F 7488 single nucleotide polymorphism and inflammatory bowel disease in the Chinese population. Scand J Gastroenterol 2009;44:720-6. [PMID: 19263269 DOI: 10.1080/00365520902795430] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 133 |
Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T, Voorhees JJ, Abecasis GR, Nair RP. Molecular dissection of psoriasis: integrating genetics and biology. J Invest Dermatol 2010;130:1213-26. [PMID: 19812592 DOI: 10.1038/jid.2009.319] [Cited by in Crossref: 202] [Cited by in F6Publishing: 212] [Article Influence: 14.4] [Reference Citation Analysis]
|
| 134 |
Narumiya S. Prostanoids and inflammation: a new concept arising from receptor knockout mice. J Mol Med 2009;87:1015-1022. [DOI: 10.1007/s00109-009-0500-1] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 135 |
Guan Q, Ma Y, Hillman CL, Ma A, Zhou G, Qing G, Peng Z. Development of recombinant vaccines against IL-12/IL-23 p40 and in vivo evaluation of their effects in the downregulation of intestinal inflammation in murine colitis. Vaccine 2009;27:7096-104. [PMID: 19786142 DOI: 10.1016/j.vaccine.2009.09.058] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 136 |
Siegmund B, Zeitz M. Clinical aspects of inflammatory bowel disease. Eur J Immunol 2009;39:2026-30. [PMID: 19672897 DOI: 10.1002/eji.200939601] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 137 |
Knight JC. Genetics and the general physician: insights, applications and future challenges. QJM 2009;102:757-72. [PMID: 19737788 DOI: 10.1093/qjmed/hcp115] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 138 |
Hibi T, Sameshima Y, Sekiguchi Y, Hisatome Y, Maruyama F, Moriwaki K, Shima C, Saniabadi AR, Matsumoto T. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis 2009;41:570-7. [PMID: 19211314 DOI: 10.1016/j.dld.2008.11.020] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 139 |
Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, Sugimoto Y, Narumiya S. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med. 2009;15:633-640. [PMID: 19465928 DOI: 10.1038/nm.1968] [Cited by in Crossref: 424] [Cited by in F6Publishing: 434] [Article Influence: 30.3] [Reference Citation Analysis]
|
| 140 |
Shen XY, Shi RH. Research progress in susceptible genes of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2009; 17(16): 1591-1601 [DOI: 10.11569/wcjd.v17.i16.1591] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 141 |
Waldner MJ, Neurath MF. Colitis-associated cancer: the role of T cells in tumor development. Semin Immunopathol 2009;31:249-56. [DOI: 10.1007/s00281-009-0161-8] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 142 |
Martins AJ, Colquhoun P, Reid G, Kim SO. Reduced expression of basal and probiotic-inducible G-CSF in intestinal mononuclear cells is associated with inflammatory bowel disease. Inflamm Bowel Dis 2009;15:515-25. [PMID: 19058228 DOI: 10.1002/ibd.20808] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 143 |
Elder JT. Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes Immun 2009;10:201-9. [PMID: 19262574 DOI: 10.1038/gene.2009.11] [Cited by in Crossref: 100] [Cited by in F6Publishing: 109] [Article Influence: 7.1] [Reference Citation Analysis]
|
| 144 |
Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin LS, Centola M, Li X. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis 2009;15:341-52. [PMID: 18942757 DOI: 10.1002/ibd.20753] [Cited by in Crossref: 513] [Cited by in F6Publishing: 489] [Article Influence: 36.6] [Reference Citation Analysis]
|
| 145 |
Glas J, Seiderer J, Pasciuto G, Tillack C, Diegelmann J, Pfennig S, Konrad A, Schmechel S, Wetzke M, Török HP, Stallhofer J, Jürgens M, Griga T, Klein W, Epplen JT, Schiemann U, Mussack T, Lohse P, Göke B, Ochsenkühn T, Folwaczny M, Müller-Myhsok B, Brand S. rs224136 on chromosome 10q21.1 and variants in PHOX2B, NCF4, and FAM92B are not major genetic risk factors for susceptibility to Crohn's disease in the German population. Am J Gastroenterol 2009;104:665-72. [PMID: 19262523 DOI: 10.1038/ajg.2008.65] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 146 |
Kim W, McMurray DN, Chapkin RS. Chemotherapeutic Properties of n-3 Polyunsaturated Fatty Acids - Old Concepts and New Insights. Immunol Endocr Metab Agents Med Chem 2009;9:38-44. [PMID: 19823600 DOI: 10.2174/187152209788009841] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 147 |
Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2009;15:300-10. [PMID: 18626975 DOI: 10.1002/ibd.20602] [Cited by in Crossref: 362] [Cited by in F6Publishing: 356] [Article Influence: 25.9] [Reference Citation Analysis]
|
| 148 |
Yang Y, Xu J, Niu Y, Bromberg JS, Ding Y. T-bet and eomesodermin play critical roles in directing T cell differentiation to Th1 versus Th17. J Immunol. 2008;181:8700-8710. [PMID: 19050290 DOI: 10.4049/jimmunol.181.12.8700] [Cited by in Crossref: 84] [Cited by in F6Publishing: 92] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 149 |
Wolowczuk I, Allez M, Chamaillard M. IL-17/23, potential targets for Crohn’s disease. Th 17 Cells: Role in Inflammation and Autoimmune Disease 2009. [DOI: 10.1007/978-3-7643-8681-8_18] [Reference Citation Analysis]
|
| 150 |
Wollheim FA. Enteropathic Arthritis. Kelley's Textbook of Rheumatology 2009. [DOI: 10.1016/b978-1-4160-3285-4.10073-7] [Reference Citation Analysis]
|
| 151 |
Fichtner-Feigl S, Young CA, Kitani A, Geissler EK, Schlitt HJ, Strober W. IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology 2008;135:2003-13, 2013.e1-7. [PMID: 18938165 DOI: 10.1053/j.gastro.2008.08.055] [Cited by in Crossref: 116] [Cited by in F6Publishing: 125] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 152 |
Aldhous MC, Prescott RJ, Roberts S, Samuel K, Waterfall M, Satsangi J. Does nicotine influence cytokine profile and subsequent cell cycling/apoptotic responses in inflammatory bowel disease? Inflamm Bowel Dis 2008;14:1469-82. [PMID: 18618634 DOI: 10.1002/ibd.20523] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 153 |
Neurath MF. IL-12 family members in experimental colitis. Mucosal Immunol 2008;1 Suppl 1:S28-30. [PMID: 19079224 DOI: 10.1038/mi.2008.45] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 154 |
Lakatos PL, Szamosi T, Szilvasi A, Molnar E, Lakatos L, Kovacs A, Molnar T, Altorjay I, Papp M, Tulassay Z, Miheller P, Papp J, Tordai A, Andrikovics H; Hungarian IBD Study Group. ATG16L1 and IL23 receptor (IL23R) genes are associated with disease susceptibility in Hungarian CD patients. Dig Liver Dis 2008;40:867-73. [PMID: 18499543 DOI: 10.1016/j.dld.2008.03.022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 48] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 155 |
Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P; Ustekinumab Crohn's Disease Study Group. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;135:1130-41. [PMID: 18706417 DOI: 10.1053/j.gastro.2008.07.014] [Cited by in Crossref: 577] [Cited by in F6Publishing: 608] [Article Influence: 38.5] [Reference Citation Analysis]
|
| 156 |
Bandyopadhyay SK, de la Motte CA, Kessler SP, Hascall VC, Hill DR, Strong SA. Hyaluronan-mediated leukocyte adhesion and dextran sulfate sodium-induced colitis are attenuated in the absence of signal transducer and activator of transcription 1. Am J Pathol. 2008;173:1361-1368. [PMID: 18818378 DOI: 10.2353/ajpath.2008.080444] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 157 |
Dessein R, Chamaillard M, Danese S. Innate immunity in Crohn's disease: the reverse side of the medal. J Clin Gastroenterol 2008;42 Suppl 3 Pt 1:S144-7. [PMID: 18806708 DOI: 10.1097/MCG.0b013e3181662c90] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 158 |
Müller-quernheim J, Schürmann M, Hofmann S, Gaede KI, Fischer A, Prasse A, Zissel G, Schreiber S. Genetics of Sarcoidosis. Clinics in Chest Medicine 2008;29:391-414. [DOI: 10.1016/j.ccm.2008.03.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 60] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 159 |
Hölttä V, Klemetti P, Sipponen T, Westerholm-Ormio M, Kociubinski G, Salo H, Räsänen L, Kolho KL, Färkkilä M, Savilahti E, Vaarala O. IL-23/IL-17 immunity as a hallmark of Crohn's disease. Inflamm Bowel Dis 2008;14:1175-84. [PMID: 18512248 DOI: 10.1002/ibd.20475] [Cited by in Crossref: 149] [Cited by in F6Publishing: 139] [Article Influence: 9.9] [Reference Citation Analysis]
|
| 160 |
Kamada N, Hisamatsu T, Okamoto S, Chinen H, Kobayashi T, Sato T, Sakuraba A, Kitazume MT, Sugita A, Koganei K, Akagawa KS, Hibi T. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest. 2008;118:2269-2280. [PMID: 18497880 DOI: 10.1172/jci34610] [Cited by in Crossref: 118] [Cited by in F6Publishing: 305] [Article Influence: 7.9] [Reference Citation Analysis]
|
| 161 |
Yuan Q, Li PD, Li BH, Yang XZ, Xu SB, Liu XH, Zhou FX, Zhang WJ. Differential IL-4/Stat6 activities correlate with differential expression of regulatory genes SOCS-1, SHP-1, and PP2A in colon cancer cells. J Cancer Res Clin Oncol 2009;135:131-40. [PMID: 18536936 DOI: 10.1007/s00432-008-0429-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 162 |
Rahman P, Inman RD, Gladman DD, Reeve JP, Peddle L, Maksymowych WP. Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum. 2008;58:1020-1025. [PMID: 18383363 DOI: 10.1002/art.23389] [Cited by in Crossref: 132] [Cited by in F6Publishing: 137] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 163 |
Hanai H, Iida T, Takeuchi K, Watanabe F, Yamada M, Kikuyama M, Maruyama Y, Iwaoka Y, Hirayama K, Nagata S, Takai K. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. Am J Gastroenterol 2008;103:1210-6. [PMID: 18177452 DOI: 10.1111/j.1572-0241.2007.01714.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 164 |
Baptista ML, Amarante H, Picheth G, Sdepanian VL, Peterson N, Babasukumar U, Lima HC, Kugathasan S. CARD15 and IL23R influences Crohn's disease susceptibility but not disease phenotype in a Brazilian population. Inflamm Bowel Dis 2008;14:674-9. [PMID: 18200510 DOI: 10.1002/ibd.20372] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 165 |
Requena P, Daddaoua A, Martínez-Plata E, González M, Zarzuelo A, Suárez MD, Sánchez de Medina F, Martínez-Augustin O. Bovine glycomacropeptide ameliorates experimental rat ileitis by mechanisms involving downregulation of interleukin 17. Br J Pharmacol 2008;154:825-32. [PMID: 18536735 DOI: 10.1038/bjp.2008.138] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 166 |
Seiderer J, Elben I, Diegelmann J, Glas J, Stallhofer J, Tillack C, Pfennig S, Jürgens M, Schmechel S, Konrad A, Göke B, Ochsenkühn T, Müller-Myhsok B, Lohse P, Brand S. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis 2008;14:437-45. [PMID: 18088064 DOI: 10.1002/ibd.20339] [Cited by in Crossref: 246] [Cited by in F6Publishing: 238] [Article Influence: 16.4] [Reference Citation Analysis]
|
| 167 |
Villarino AV, Artis D, Bezbradica JS, Miller O, Saris CJ, Joyce S, Hunter CA. IL-27R deficiency delays the onset of colitis and protects from helminth-induced pathology in a model of chronic IBD. Int Immunol. 2008;20:739-752. [PMID: 18375937 DOI: 10.1093/intimm/dxn032] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 168 |
Shih TC, Hsieh SY, Hsieh YY, Chen TC, Yeh CY, Lin CJ, Lin DY, Chiu CT. Aberrant activation of nuclear factor of activated T cell 2 in lamina propria mononuclear cells in ulcerative colitis. World J Gastroenterol 2008; 14(11): 1759-1767 [PMID: 18350607 DOI: 10.3748/wjg.14.1759] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 169 |
Ramoner R, Rahm A, Gander H, Stollenwerk B, Falkensammer C, Leonhartsberger N, Thurnher M. Serum antibodies against Saccharomyces cerevisiae: a new prognostic indicator in metastatic renal-cell carcinoma. Cancer Immunol Immunother 2008;57:1207-14. [DOI: 10.1007/s00262-008-0454-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 170 |
Weersma RK, Zhernakova A, Nolte IM, Lefebvre C, Rioux JD, Mulder F, van Dullemen HM, Kleibeuker JH, Wijmenga C, Dijkstra G. ATG16L1 and IL23R are associated with inflammatory bowel diseases but not with celiac disease in the Netherlands. Am J Gastroenterol 2008;103:621-7. [PMID: 18047540 DOI: 10.1111/j.1572-0241.2007.01660.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 77] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 171 |
Schmechel S, Konrad A, Diegelmann J, Glas J, Wetzke M, Paschos E, Lohse P, Göke B, Brand S. Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. Inflamm Bowel Dis 2008;14:204-12. [PMID: 18022867 DOI: 10.1002/ibd.20315] [Cited by in Crossref: 142] [Cited by in F6Publishing: 132] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 172 |
Bousvaros A, Morley-Fletcher A, Pensabene L, Cucchiara S. Research and clinical challenges in paediatric inflammatory bowel disease. Dig Liver Dis 2008;40:32-8. [PMID: 17996504 DOI: 10.1016/j.dld.2007.07.168] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 173 |
Mathew CG. New links to the pathogenesis of Crohn disease provided by genome-wide association scans. Nat Rev Genet 2008;9:9-14. [PMID: 17968351 DOI: 10.1038/nrg2203] [Cited by in Crossref: 143] [Cited by in F6Publishing: 158] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 174 |
Fiasse R, Dewit O. Novel therapies based on enhancement of gut innate immunity in inflammatory bowel disease. Expert Opinion on Therapeutic Patents 2007;17:1423-41. [DOI: 10.1517/13543776.17.12.1423] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 175 |
Pang YH, Zheng CQ, Yang XZ, Zhang WJ. Increased expression and activation of IL-12-induced Stat4 signaling in the mucosa of ulcerative colitis patients. Cell Immunol. 2007;248:115-120. [PMID: 18048021 DOI: 10.1016/j.cellimm.2007.10.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 176 |
Christophers E. Explaining phenotype heterogeneity in patients with psoriasis: Explaining phenotype heterogeneity in psoriasis. British Journal of Dermatology 2008;158:437-41. [DOI: 10.1111/j.1365-2133.2007.08307.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 177 |
Tung J, Sandborn WJ. Biologic Therapies. Pediatric Inflammatory Bowel Disease. [DOI: 10.1007/978-0-387-73481-1_32] [Reference Citation Analysis]
|
| 178 |
Preiß J, Duchmann R. Neue Therapieverfahren bei chronisch-entzündlichen Darmerkrankungen. Gastroenterologe 2007;2:423-429. [DOI: 10.1007/s11377-007-0117-2] [Reference Citation Analysis]
|
| 179 |
Saniabadi AR, Hanai H, Fukunaga K, Sawada K, Shima C, Bjarnason I, Lofberg R. Therapeutic leukocytapheresis for inflammatory bowel disease. Transfus Apher Sci. 2007;37:191-200. [PMID: 17974479 DOI: 10.1016/j.transci.2007.08.003] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 180 |
van der Woude CJ, Hommes DW. Biologics in Crohn's disease: searching indicators for outcome. Expert Opin Biol Ther. 2007;7:1233-1243. [PMID: 17696821 DOI: 10.1517/14712598.7.8.1233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 181 |
Glas J, Seiderer J, Wetzke M, Konrad A, Török HP, Schmechel S, Tonenchi L, Grassl C, Dambacher J, Pfennig S, Maier K, Griga T, Klein W, Epplen JT, Schiemann U, Folwaczny C, Lohse P, Göke B, Ochsenkühn T, Müller-Myhsok B, Folwaczny M, Mussack T, Brand S. rs1004819 is the main disease-associated IL23R variant in German Crohn's disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants. PLoS One 2007;2:e819. [PMID: 17786191 DOI: 10.1371/journal.pone.0000819] [Cited by in Crossref: 99] [Cited by in F6Publishing: 112] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 182 |
Dambacher J, Beigel F, Seiderer J, Haller D, Göke B, Auernhammer CJ, Brand S. Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease. Gut 2007;56:1257-65. [PMID: 17449633 DOI: 10.1136/gut.2006.118679] [Cited by in Crossref: 85] [Cited by in F6Publishing: 87] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 183 |
Van Limbergen J, Russell %K, Nimmo ER, Drummond HE, Smith L, Davies G, Anderson NH, Gillett PM, Mcgrogan P, Hassan K, Weaver L, Bisset WM, Mahdi G, Wilson DC, Satsangi J. IL23R Arg381Gln is associated with childhood onset inflammatory bowel disease in Scotland. Gut 2007;56:1173-1174. [DOI: 10.1136/gut.2007.122069] [Cited by in Crossref: 69] [Cited by in F6Publishing: 72] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 184 |
Ferguson LR, Shelling AN, Browning BL, Huebner C, Petermann I. Genes, diet and inflammatory bowel disease. Mutat Res. 2007;622:70-83. [PMID: 17628615 DOI: 10.1016/j.mrfmmm.2007.05.011] [Cited by in Crossref: 68] [Cited by in F6Publishing: 73] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 185 |
Duerr RH. Genome-wide association studies herald a new era of rapid discoveries in inflammatory bowel disease research. Gastroenterology 2007;132:2045-9. [PMID: 17484895 DOI: 10.1053/j.gastro.2007.03.082] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
|
